Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Generated: June 22, 2018

DrugPatentWatch Database Preview

Adapt Company Profile

« Back to Dashboard

What is the competitive landscape for ADAPT, and when can generic versions of ADAPT drugs launch?

ADAPT has two approved drugs.

There are seven US patents protecting ADAPT drugs.

There are fifteen patent family members on ADAPT drugs in twelve countries and one supplementary protection certificate in one country.

Summary for Adapt

International Patents:	15
US Patents:	7
Tradenames:	1
Ingredients:	1
NDAs:	2

Drugs and US Patents for Adapt

+ Get email alerts for changes to this table

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Adapt	NARCAN	naloxone hydrochloride	SPRAY, METERED;NASAL	208411-001	Nov 18, 2015		RX	Yes	Yes	9,211,253	➤ Try a Free Trial	Y			➤ Try a Free Trial
Adapt	NARCAN	naloxone hydrochloride	SPRAY, METERED;NASAL	208411-001	Nov 18, 2015		RX	Yes	Yes	9,629,965	➤ Try a Free Trial	Y			➤ Try a Free Trial
Adapt	NARCAN	naloxone hydrochloride	INJECTABLE;INJECTION	016636-003	Jun 14, 1982		DISCN	Yes	No		➤ Try a Free Trial				➤ Try a Free Trial
Adapt	NARCAN	naloxone hydrochloride	INJECTABLE;INJECTION	016636-002	Approved Prior to Jan 1, 1982		DISCN	Yes	No		➤ Try a Free Trial				➤ Try a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration

Paragraph IV (Patent) Challenges for ADAPT drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Nasal Spray	4 mg/spray	➤ Subscribe	2016-07-15

International Patents for Adapt Drugs

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Country	Document Number	Estimated Expiration
United Kingdom	201616616	➤ Try a Free Trial
Singapore	11201607281P	➤ Try a Free Trial
Spain	2631504	➤ Try a Free Trial
Australia	2015228541	➤ Try a Free Trial
Country	Document Number	Estimated Expiration

Supplementary Protection Certificates for Adapt Drugs

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
292	Luxembourg	➤ Try a Free Trial	PRODUCT NAME: COMBINAISON D OXYCODONE EN TANT QUE COMPOSANT A ET DE NALOXONE EN TANT QUE COMPOSANT B SOUS TOUTES LES FORMES PROTEGES PAR LE BREVET DE BASE
Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Adapt

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo

Farmers Insurance

Boehringer Ingelheim

Moodys

Queensland Health

Federal Trade Commission

AstraZeneca

Julphar

Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.